Andrew Cheng Akero Therapeutics, Inc. (AKRO) insider trading activity

Andrew Cheng is President and CEO of Akero Therapeutics, Inc.. Currently has a direct ownership of 605,417 shares of AKRO, which is worth approximately $17.1 Million. The most recent transaction as insider was on Jul 03, 2023, when has been sold 25,000 shares (Common Stock) at a price of $6.36 per share, resulting in proceeds of $159,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 605K

3.91% 3M change

31.33% 12M change

Total Value Held $17.1 Million

Andrew Cheng Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 03 2023	BUY Exercise of conversion of derivative security	$159,000 $6.36 p/Share	25,000 Added 5.02%	472,680 Common Stock
Jun 27 2023	BUY Exercise of conversion of derivative security	$24,800 $0.62 p/Share	40,000 Added 8.2%	447,680 Common Stock
Jun 13 2023	SELL Open market or private sale	$88,973 $55.16 p/Share	1,613 Reduced 0.39%	407,680 Common Stock
Jun 01 2023	SELL Open market or private sale	$1,127,750 $45.11 p/Share	25,000 Reduced 5.76%	409,293 Common Stock
Jun 01 2023	BUY Exercise of conversion of derivative security	$87,250 $3.49 p/Share	25,000 Added 5.44%	434,293 Common Stock
May 01 2023	SELL Open market or private sale	$1,131,250 $45.25 p/Share	25,000 Reduced 5.76%	409,293 Common Stock
May 01 2023	BUY Exercise of conversion of derivative security	$15,500 $0.62 p/Share	25,000 Added 5.44%	434,293 Common Stock
Apr 18 2023	BUY Exercise of conversion of derivative security	$24,800 $0.62 p/Share	40,000 Added 8.9%	409,293 Common Stock
Apr 03 2023	SELL Open market or private sale	$959,000 $38.36 p/Share	25,000 Reduced 6.34%	369,293 Common Stock
Apr 03 2023	BUY Exercise of conversion of derivative security	$15,500 $0.62 p/Share	25,000 Added 5.96%	394,293 Common Stock
Mar 10 2023	SELL Payment of exercise price or tax liability	$74,159 $43.47 p/Share	1,706 Reduced 0.46%	369,293 Common Stock
Mar 01 2023	SELL Open market or private sale	$1,161,000 $46.44 p/Share	25,000 Reduced 6.31%	370,999 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	$15,500 $0.62 p/Share	25,000 Added 5.94%	395,999 Common Stock
Feb 01 2023	SELL Open market or private sale	$1,236,500 $49.46 p/Share	25,000 Reduced 6.31%	370,999 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	$15,500 $0.62 p/Share	25,000 Added 5.94%	395,999 Common Stock
Jan 03 2023	SELL Open market or private sale	$1,313,500 $52.54 p/Share	25,000 Reduced 6.31%	370,999 Common Stock
Jan 03 2023	BUY Exercise of conversion of derivative security	$15,500 $0.62 p/Share	25,000 Added 5.94%	395,999 Common Stock
Dec 16 2022	BUY Exercise of conversion of derivative security	$5,270 $0.62 p/Share	8,500 Added 2.24%	370,999 Common Stock
Dec 09 2022	BUY Grant, award, or other acquisition	-	52,351 Added 12.62%	362,499 Common Stock
Dec 01 2022	SELL Open market or private sale	$460,700 $46.07 p/Share	10,000 Reduced 3.12%	310,148 Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.03%	320,148 Common Stock
Nov 01 2022	SELL Open market or private sale	$432,100 $43.21 p/Share	10,000 Reduced 3.12%	310,148 Common Stock
Nov 01 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.03%	320,148 Common Stock
Oct 03 2022	SELL Open market or private sale	$335,900 $33.59 p/Share	10,000 Reduced 3.12%	310,148 Common Stock
Oct 03 2022	BUY Exercise of conversion of derivative security	$6,200 $0.62 p/Share	10,000 Added 3.03%	320,148 Common Stock

Also insider at

VERA

Vera Therapeutics, Inc. Healthcare

ABUS

Arbutus Biopharma Corp Healthcare

Director

Andrew Cheng

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Value

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

Operation

Value

Type

News

Receive news related to Akero Therapeutics, Inc.

Track Activities on AKRO

Account